AnaptysBio, Inc. (ANAB)

AnaptysBio's stock price has been significantly impacted by several key events including a substantial beat in its fourth-quarter 2025 financial results, the spin-off of its biopharma operations into First Tracks Biotherapeutics, the approval of a $100 million stock repurchase program, a favorable ruling from the Delaware Chancery Court dismissing Tesaro's anticipatory breach claim, and the publication of pivotal Phase 3 data for Imsidolimab in NEJM Evidence. These events contributed to a significant increase in the stock price. Upcoming events include an FDA decision for Imsidolimab targeted for December 2026 and a trial in July 2026 to adjudicate AnaptysBio's contract claims and right to seek reversion of Jemperli against Tesaro/GSK.

There is no direct information to suggest demand seasonality for AnaptysBio's products and services in the traditional sense. While there may be seasonal patterns in its stock performance, this does not reflect seasonality in product demand.

AnaptysBio is a clinical-stage biotechnology company focused on developing immunology therapeutics for autoimmune and inflammatory diseases, utilizing its Somatic Hypermutation (SHM) platform to develop therapeutic-grade antibodies. Its pipeline has included Rosnilimab, ANB033 and ANB101. AnaptysBio also has out-licensed therapeutic antibodies, including Dostarlimab (Jemperli) and Imsidolimab. In April 2026, AnaptysBio completed the spin-off of its biopharma operations into First Tracks Biotherapeutics and now exclusively manages the financial collaborations for Jemperli and Imsidolimab.

AnaptysBio is headquartered in San Diego, California, United States. Its partnerships with global pharmaceutical companies imply a broader market reach for its partnered products.

AnaptysBio has generally maintained a positive brand reputation, reflected in a "Moderate Buy" consensus rating from analysts. Positive events such as the favorable Delaware Chancery Court ruling regarding Jemperli royalty rights and the publication of positive Phase 3 data for Imsidolimab in NEJM Evidence have bolstered its reputation. The strategic spin-off of its biopharma operations is also viewed as a move to unlock value for shareholders. However, potential risks to its reputation include a history of clinical trial failures and discontinued programs, an uncertain commercialization strategy for rosnilimab, and competitive threats. Ongoing litigation with Tesaro and GSK, despite a recent favorable ruling, presents a continued legal challenge.

AnaptysBio has a significant institutional ownership base, with major institutional shareholders including EcoR1 Capital, LLC, Point72 Asset Management, L.P., BlackRock, Inc., Vanguard Group Inc, Tang Capital Management Llc, State Street Corp, Morgan Stanley, Sanofi, Millennium Management Llc, and D. E. Shaw & Co., Inc. EcoR1 Capital LLC is also identified as a significant individual shareholder. Other notable insider owners include Oleg Nodelman, Avalon Ventures VII L P, Holdings A. Novo, and Frazier Healthcare VII LP.